Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.31 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516162 | 0.80 | TDP1 (0.44) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL28010031 | 0.70 | BCAT2 (0.32) | BCAT2 | |
| SCHEMBL5508581 | 0.70 | BCAT2 (0.42) | BCAT2 | |
| SCHEMBL5508575 | 0.70 | BCAT2 (0.42) | BCAT2 | |
| SCHEMBL28276738 | 0.69 | GAA (0.59) | — | |
| SCHEMBL28276739 | 0.69 | GAA (0.59) | — | |
| SCHEMBL2160129 | 0.67 | ALDH1A1 (0.41) | BCAT2 | |
| SCHEMBL2160122 | 0.67 | ALDH1A1 (0.41) | BCAT2 | |
| SCHEMBL890126 | 0.67 | BCAT2 (0.36) | DYRK1ABCAT2 | |
| SCHEMBL13863261 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | CCNA2 1590/4885CDK2 814/4885CCNA1 499/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | CCNA2 1590/4885CDK2 814/4885CCNA1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.